Early and delayed benefits of HIV-1 suppression: Timeline of recovery of innate immunity effector cells

Keyphrases

• Antiretroviral Therapy 50%
• CD123 50%
• CD4% 100%
• Cell Changes 50%
• Cell Recovery 50%
• Cryopreserved 50%
• Days of Therapy 50%
• Delayed Benefits 100%
• Early Benefit 100%
• Effector Cells 100%
• Flow Cytometry 50%
• Functional Parameters 50%
• Human Immunodeficiency Virus Type 1 (HIV-1) 100%
• Innate Immune Effectors 50%
• Innate Immunity 100%
• Interferon Production 50%
• Killer Dendritic Cells 100%
• Linear Splines 50%
• Mixed-effects Model 50%
• Multicenter AIDS Cohort Study 50%
• Myeloid Dendritic Cells 50%
• Natural Killer Cell Subsets 50%
• Natural Killer T 50%
• Negative Effects 50%
• Plasmacytoid 50%
• Plasmacytoid Dendritic Cells 100%
• Rapid Rise 50%
• T Cell Activation 50%
• T Cell Subsets 50%
• T Cells 50%
• Viral Suppression 50%
• Viremic 50%
• White Blood Cell Count 50%
• Women's Interagency HIV Study 50%

Immunology and Microbiology

• CD4 100%
• Dendritic Cell 33%
• Effector Cell 100%
• Human Immunodeficiency Virus 33%
• Human Immunodeficiency Virus 1 100%
• Innate Immune System 100%
• Interferon Production 33%
• Leukocyte Count 33%
• Myeloid Dendritic Cell 33%
• Natural Killer Cell 66%
• Plasmacytoid Dendritic Cell 66%
• T Cell 33%
• T Cell Activation 33%
• T Cell Subset 33%